XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
NURO NeuroMetrix
- 4.379
- -0.001-0.03%
Close Feb 14 16:00 ET
- 4.379
- 0.0000.00%
Post 20:01 ET
8.94MMarket Cap-0.97P/E (TTM)
4.380High4.360Low4.82KVolume4.360Open4.380Pre Close21.01KTurnover0.29%Turnover RatioLossP/E (Static)2.04MShares4.73052wk High0.56P/B7.36MFloat Cap2.66052wk Low--Dividend TTM1.68MShs Float3736244.330Historical High--Div YieldTTM0.45%Amplitude2.660Historical Low4.362Avg Price1Lot Size
NeuroMetrix Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -51.19%587.31K | -53.55%769.15K | -36.60%1.09M | -28.52%5.9M | -28.67%1.32M | -38.86%1.2M | -22.57%1.66M | -25.09%1.72M | 0.03%8.26M | 1.50%1.85M |
| Operating revenue | -51.19%587.31K | -53.55%769.15K | -36.60%1.09M | -28.52%5.9M | -28.67%1.32M | -38.86%1.2M | -22.57%1.66M | -25.09%1.72M | 0.03%8.26M | 1.50%1.85M |
| Cost of revenue | -34.65%275.36K | -48.33%277.23K | 9.53%576.54K | -22.02%1.95M | -23.89%469.77K | -39.24%421.38K | -21.81%536.49K | 3.44%526.37K | 7.46%2.51M | 6.89%617.27K |
| Gross profit | -60.10%311.96K | -56.05%491.92K | -56.86%517.02K | -31.35%3.95M | -31.07%847.97K | -38.66%781.78K | -22.93%1.12M | -33.18%1.2M | -2.89%5.75M | -1.01%1.23M |
| Operating expense | -25.11%2.05M | -15.39%2.32M | 29.66%3.77M | 5.78%11.1M | 29.64%2.71M | -8.19%2.74M | 3.01%2.74M | 5.55%2.91M | 27.85%10.49M | -7.15%2.09M |
| Selling and administrative expenses | -18.41%1.75M | 3.24%2.05M | 27.99%2.83M | 14.74%8.32M | 27.42%1.97M | 12.42%2.15M | 13.88%1.99M | 8.03%2.21M | 29.28%7.25M | 23.85%1.55M |
| -Selling and marketing expense | -53.26%441.17K | -41.61%435.01K | 30.13%1.06M | 17.44%3.37M | 36.62%860.64K | 16.49%943.8K | 31.48%744.96K | -5.00%815.87K | 76.92%2.87M | 22.52%629.97K |
| -General and administrative expense | 8.86%1.31M | 30.09%1.62M | 26.74%1.77M | 12.97%4.96M | 21.11%1.11M | 9.43%1.21M | 5.44%1.24M | 17.46%1.39M | 9.94%4.39M | 24.77%918.21K |
| Research and development costs | -49.42%299.74K | -64.57%266.93K | 34.90%943.55K | -14.25%2.78M | 36.03%732.37K | -44.87%592.65K | -17.72%753.51K | -1.57%699.43K | 24.78%3.24M | -46.00%538.4K |
| Operating profit | 11.16%-1.74M | -12.64%-1.83M | -90.28%-3.25M | -50.82%-7.15M | -116.83%-1.86M | -14.47%-1.96M | -34.13%-1.62M | -77.76%-1.71M | -107.55%-4.74M | 14.74%-856.47K |
| Net non-operating interest income expense | -66.85%8.41K | -84.95%13.01K | -85.90%19.16K | -20.93%257.11K | -94.29%9.41K | -76.22%25.38K | 86.43K | 135.9K | 10,222.44%325.16K | 164.6K |
| Non-operating interest income | -66.85%8.41K | -84.95%13.01K | -85.90%19.16K | -20.93%257.11K | -94.29%9.41K | -76.22%25.38K | --86.43K | --135.9K | 10,222.44%325.16K | --164.6K |
| Other net income (expense) | 35.15%225.41K | 327.72K | 205.26K | 364.93K | 198.15K | 166.78K | ||||
| Other non- operating income (expenses) | 35.15%225.41K | --327.72K | --205.26K | --364.93K | --198.15K | --166.78K | ---- | ---- | ---- | ---- |
| Income before tax | 14.73%-1.51M | 3.19%-1.49M | -92.45%-3.03M | -47.84%-6.53M | -138.42%-1.65M | -10.12%-1.77M | -32.51%-1.54M | -64.22%-1.57M | -93.59%-4.42M | 31.02%-691.87K |
| Income tax | ||||||||||
| Net income | 14.73%-1.51M | 3.19%-1.49M | -92.45%-3.03M | -47.84%-6.53M | -138.42%-1.65M | -10.12%-1.77M | -32.51%-1.54M | -64.22%-1.57M | -93.59%-4.42M | 31.02%-691.87K |
| Net income continuous Operations | 14.73%-1.51M | 3.19%-1.49M | -92.45%-3.03M | -47.84%-6.53M | -138.42%-1.65M | -10.12%-1.77M | -32.51%-1.54M | -64.22%-1.57M | -93.59%-4.42M | 31.02%-691.87K |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 14.73%-1.51M | 3.19%-1.49M | -92.45%-3.03M | -47.84%-6.53M | -138.42%-1.65M | -10.12%-1.77M | -32.51%-1.54M | -64.22%-1.57M | -93.59%-4.42M | 31.02%-691.87K |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 14.73%-1.51M | 3.19%-1.49M | -92.45%-3.03M | -47.84%-6.53M | -138.42%-1.65M | -10.12%-1.77M | -32.51%-1.54M | -64.22%-1.57M | -93.59%-4.42M | 31.02%-691.87K |
| Basic earnings per share | 54.82%-0.75 | 52.56%-0.74 | -1.83%-1.67 | -26.16%-6.27 | -52.16%-1.0817 | 9.78%-1.66 | -14.71%-1.56 | -46.43%-1.64 | -38.06%-4.97 | 40.81%-0.7109 |
| Diluted earnings per share | 54.82%-0.75 | 52.56%-0.74 | -1.83%-1.67 | -26.16%-6.27 | -52.16%-1.0817 | 9.78%-1.66 | -14.71%-1.56 | -46.43%-1.64 | -38.06%-4.97 | 40.81%-0.7109 |
| Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!